A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)

Overview of attention for article published in Investigational New Drugs, February 2017

Altmetric Badge

Mentioned by

facebook: 1 Facebook page

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 32 Mendeley

Summary Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

日本がん対策新聞, 05 Feb 2017

《短報》【肺がん(≧70歳)：一次治療】日本のPhase 2試験『NEJ016』試験の結果。「カルボプラチン＋パクリタキセル＋アバスチン」の奏効率69.7%、無増悪生存期間8.4ヵ月、生存期間29.2ヵ月。〔Invest New Drugs〕 https…